We studied the bias and precision of serum cholesterol analysis by physician's office analyzers. Total imprecision (CV range, %) for analysis of serum pools was: Abbott Vision 1.5%-1 .9%; Ames Seralyzer 3.9%-4.5%; BMD Reflotron 2.3%-3.8%;
provide guidance for manufacturers of these types of devices. The baseline data for product performance can be useful in assessing significant modifications of diagnostic tests involving determination of cholesterol. The information should also assist in the consumer-education activities of the National Heart, Lung, and Blood Institute's National Cholesterol Education Program regarding increased concentrations of cholesterol as a risk factor in coronary heart disease.
Materials and Methods

Instrument Systems
All instrument systems are based on the use of coupled enzymatic reagent systems: cholesterol esterase (EC 3.1.1.13), cholesterol oxidase (EC 1.1.3.6), peroxidase (EC 1.11.1.7), and various chromogens.
Abbott Vision Analyzer (Abbott Laboratories, North Chicago, IL 60064). Serum or whole blood is introduced into a test cassette; the analyzer centrifuges the sample, decants a volume of serum or plasma, and mixes the sample with the reagents. Colorimetric measurements are used. This centrifugal analyzer is unique in its ability to separate whole blood, decant the sample and mix it with reagents, and perform multiple colorimetric measurements, all without operator intervention.
Ames Seralyzer (Ames Division, Miles Laboratories, Inc., Elkhart, IN 46515). Sample is manually diluted and applied to a reagent pad attached to a plastic strip. When the strip is inserted into the analyzer, automatic circuitry directs timed measurements by reflectance photometry of the color density on the reagent strip.
BMD Reflotron (Boehringer Mannheim Diagnostics Division, Indianapolis, IN 46250). Essentially similar in principle to the Ames Seralyzer, the Reflotron does not require sample dilution and has the additional capability to accept a whole-blood sample and remove cells by adhesion to glass fibers.
Chrometrics Cholesterol Test System (Chrometrics Laboratories Inc., Park Ridge, IL 60068). This system consists of a capillary centrifuge, a computer-controlled photometer, capillaries, and reagent-filled cuvettes. Conventional enzymatic reactions with a liquid reagent are used.
Kodak DT-60 (Eastman Kodak Co., Rochester, NY 14650). The sample is manually applied to the test area of a slide, on which reagents are present in multiple dried layers. Color intensity is measured by reflectance photometry.
Controls and Pools
For each analytical nm for each instrument system, we included freshly prepared portions of (a) controls provided or recommended by the instrument manufacturer (used to evaluate the success of each run); (b) normal, abnormal, and elevated lipid controls (Fisher Scientific Co., Pittsburgh, PA 15219), and (c) three frozen human serum pools provided by the Clinical Chemistry Division, CDC, Atlanta, GA 30333. The cholesterol concentration values supplied for the CDC From each subject we collected: (a) by venipuncture, whole blood into one 10-mL tube containing lithium heparin, from which plasma was separated; (b) from a fingerstick, samples in three heparinized capillary tubes (one each of the type recommended for use with the Abbott, BMD, and Chrometrics instruments); (c) also by venipuncture, whole blood in a 10-mL tube with no additive, from which we removed a small quantity of whole blood in heparinized capillaries (for use with some instruments); afterwards, this 10-mL sample was centrifuged to recover serum.
All specimens were analyzed within 30 mm after collection. Excess serum was stored at -20 #{176}C in two screwcapped plastic vials for shipment to the CDC.
Analysis
All specimens were analyzed with each instrument immediately after collection, by a single technologist who was trained in the operation of each instrument by the respective manufacturer's representative. At the beginning and end of each run, we validated the proper functioning of each system by analyzing controls provided or recommended by instrument manufacturers.
Calibration was performed at the frequency recommended by each manufacturer, or when quality-control results exceeded established criteria. For comparison, serum specimens were analyzed in duplicate at the CDC, by the proposed cholesterol Reference Method (5). The CDC was not provided with other test results until after the analyses were completed. these data (by analysis of variance) to estimate within-run and between-run components of imprecision ( Table lb) . The least precise system in our hands was the Ames Seralyzer-perhaps in part because it needed to be recalibrated more often than the other systems. that based on data for controls and pooled samples (total SD) ( Figure 1 and Table 1 ). (Note that S includes the pooled total imprecision for the reference and test methods; the CV for the reference method is 1%, which should little affect S, when the imprecision of the test method exceeds 2%.) For the Kodak DT-60, we found similar imprecision by both approaches. However, for the other instruments we found significantly poorer precision when testing unknown samples than when testing controls. None of the pools or controls reported here were used to evaluate the success of each run, so the effect of operator bias should be minimal. These results suggest that the Abbott Vision, BMD Reflotron, Chrometrics, and Ames methods are affected by variables in patients' samples that may differ from sample to sample. Estimates of imprecision representative of that affecting patients' results are best obtained from studies with patients' samples rather than controls or pools.
Results
Precision
For most laboratory methods, the within-run component of imprecision is greater than the between-run component because most factors (i.e., pipetting, short-term instrument noise, etc.) that influence imprecision in a rugged method Ruggedness is defined as insensitivity of method to variable environmental conditions, including variable constituents in sample matrix. (Table lb) . With the Ames Seralyzer, however, we found a significantly higher between-run than within-run component of imprecision; this suggests a lack of ruggedness in this method, which could be due to one of a number of longitudinal factors such as reagent or instrument instability.
For all instruments, we found poorer precision for assays of heparinized plasma than for serum (Table 2), although this difference was significant only for the Abbott Vision and the Kodak DT-60. In contrast, tests of fingerstick blood or venipuncture whole blood gave mixed results; in some instances precision was better, and in some worse than that for serum.
Accuracy
With four of the five instrument systems, mean values for cholesterol concentration in CDC pools were within 5% of the assigned concentrations. With the BMD Refiotron, however, results were within 5% for only one of the three pools (Table la) .
When results for patients' sera were compared with those by the proposed Reference Method (Table 2, Figure 2 ), slopes were near unity for the Abbott Vision, Ames Seralyzer, and Chrometrics analyzers. In contrast, the BMD Reflotron and the Kodak DT-60 displayed significant negative bias ( Table   2 ).
With all of the analytical systems, results were greatest with serum, lower for heparinized plasma from venous blood, for whole venous blood, and for fingerstick blood.
Linearity
We were unable to evaluate linearity directly by supplementation of serum pools with purified cholesterol; such preparations were unsuitable for analysis with some sys5Both Eastman Kodak and Boehringer Mannheim Diagnostics have notified us that, subsequent to this study (conducted in summer 1986), they modified the cholesterol calibration of their analytical systems to eliminate the bias. We have not tested these modifications. We examined patients' data for significant curvature by fitting to them a second-degree polynomial. Although some systems produced relationships that were statistically nonlinear, we judged that few of these minor deviations from linearity detract significantly from clinical use of the tests. Results with the BMD Reflotron were appreciably nonlinear for plasma, whole-blood, and fingerstick samples: nonlinearity contributed approximately 20% of the random error in those analyses.
Method(V)
Discussion
As a result of large epidemiological studies conducted over the past 30 years, an extensive database now demonstrates the important relationship between serum cholesterol and development of cardiovascular disease-the leading cause of death in the United States (1-3) . The studies that provided the basis for this knowledge utilized a methodology for measurement of cholesterol that was itself the subject of extensive testing. The proposed Reference Method that has resulted from this effort is extensively documented with regard to accuracy and precision, and has been demonstrated to be transferable among laboratories (7, 8) .
Despite these efforts, which have advanced cholesterol testing to a great level of sophistication in the reference laboratories that use the proposed Reference Method, most clinical laboratories use other, less well-documented methods; such is also the case with the various methods now marketed for use in physicians' office laboratories. Use of testing methods that are less accurate or precise than the proposed Reference Method could lead to mis-classification of patients with regard to hypercholesterolemia.
We concluded that each of the analytical systems we tested was deficient in some respect, although to different degrees.
hnprecision with pooled serum was not excessive with any system. However, several of the systems exhibited significantly greater imprecision when they were used to test patients' sera-perhaps an indication that these systems are influenced by serum components other than cholesterol concentration. Because the reference method is not without imprecision, one can expect somewhat greater imprecision (as indicated by the variation of the data about the line of best fit) in a correlation study than simply in the results for repeated testing of pooled serum. For some systems, however, the relationship between these two measw-es of imprecision clearly suggests that inter-sample variables are not adequately compensated for by method design.
The lack of ruggedness suggested by the excessive between-day component of imprecision for the Ames Seralyzer is cause for concern. A measurement system that requires extra effort to control between-day sources of variation is particularly undesirable for use in nonlaboratory settings, where such attention is likely to be lacking.
We found insignificant bias when the Abbott Vision, Chrometrics, and Ames Seralyzer systems were used to test fresh serum for cholesterol. Both the BMD Reflotron and the Kodak DT-60 exhibited negative bias. Apparently, these manufacturers have inadvertently introduced an error in calibration of their systems. 5 There are substantial limitations on the usefulness of CDC frozen serum pools for establishing method accuracy. Most systems yielded similar bias for both fresh serum and CDC pools, but the Kodak system gave discrepant estimates of bias. Pools prepared by the CDC are altered by addition of a low-density lipoprotein-rich fraction, and may also contain egg yolk extract and ethanol (9, 10). These alterations to serum pools, or subsequent freezing, may affect reactivity in some analytical systems. Ultimately, accurate calibration of each instrument system must be verifiedby comparison of test results for patients' sera with those by the proposed Reference Method.
Except for the Kodak DT-60, the instruments gave lower slopes for plasma, fingerstick blood, and whole-blood measurements of cholesterol than did the proposed Reference Method. Kupke et al. (11) reported an 8.7% negative bias for cholesterol measured in fingerstick serum compared with venous serum; the bias was attributed to lower concentrations of lipoprotein in capillary blood and to contamination with lymph. Although we found a similar decrease in results for heparin-treated fingerstick blood vs venous serum, comparable decreases were also seen with heparin-treated ye- demonstrated the in vitro suppression of cholesterol esterase activity (used in all systems studied) in the presence of heparin. Perhaps our finding of low results for heparinized specimens is due, at least in part, to incomplete de-esterification of cholesterol esters.
Moore and Boyle (13) and Martinek (14) also reported 5%-15% lower results for cholesterol in heparin-treated plasma (they used nonenzymatic methods of analysis), and attributed the effect to a "water shift" caused by the anticoagulant. This conclusion is at variance with the experience of many laboratories, which find equivalent concentrations of many analytes in serum and heparin-treated plasma. Whatever the cause, serum and heparin-treated plasma may not be analyzed interchangeably by these cholesterol test systems, as is suggested by several manufacturers. Our findings indicate that most systems should be calibrated differently for heparin-containing samples than for serum. If widespread testing for serum cholesterol is to achieve the desired effect of facilitating preventive care for individuals with hypercholesterolemia, it is essential that accurate analytical systems be made available for use in clinics and physicians' offices. We recommend that manufacturers take necessary steps to improve on the performance of analytical systems. We also recommend that users of these instrument systems request documentation of the accuracy of the test system before using the instrument for cholesterol testing.
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